BREAKWATER: encorafenib plus cetuximab in patients with BRAF V600E-mutant mCRC

The evolving treatment paradigm for BRAF V600E-mutant mCRCПодробнее

Encorafenib & Binimetinib + Cetuximab for Untreated BRAF V600E-Mutant Metastatic Colorectal CancerПодробнее

BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic ...Подробнее

FIRE-4.5: FOLFOXIRI plus either bevacizumab or cetuximab in mCRCПодробнее

Treatment approaches for BRAF V600E mutant metastatic colorectal cancerПодробнее

Dr. Lenz on Breakthrough Designation of Encorafenib, Binimetinib, and Cetuximab in BRAF+ CRCПодробнее

Dr. Bekaii-Saab on Tolerability of Encorafenib, Binimetinib, and Cetuximab in BRAF+ CRCПодробнее

First-Line Triplet in BRAF+ mCRCПодробнее

FIRE-4.5: FOLFOXIRI plus either bevacizumab or cetuximab as 1L treatment of BRAF V600E-mutant mCRCПодробнее

Triplet Regimen Improves Responses in BRAF V600E+ Metastatic CRCПодробнее

Evidence in BRAF-Mutant CRC TumorsПодробнее

BIG BANG: binimetinib, encorafenib, and cetuximab in BRAF non-V600E mutated mCRCПодробнее

New Therapy Options for BRAF-Mutated mCRCПодробнее

Updated Survival Data from BEACON CRC Lead to More Specific QuestionsПодробнее

SWOG S2107: encorafenib, cetuximab ± nivolumab in previously treated, MSS, BRAFV600E CRCПодробнее

A Phase I/II investigating the addition of IO to the standard of care for patients with MSS mCRCПодробнее

Safety Lead-In Data for BEACON CRC Trial With Triplet Biologic Regimen in mCRCПодробнее

Next Steps After Phase III BEACON CRC Trial in mCRCПодробнее

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal CancerПодробнее